Identifying and Managing Pain in People with Alzheimer’s Disease and Other Types of Dementia: A Systematic Review by Bettina S. Husebo et al.
SYSTEMATIC REVIEW
Identifying and Managing Pain in People with Alzheimer’s
Disease and Other Types of Dementia: A Systematic Review
Bettina S. Husebo1,2 • Wilco Achterberg1,3 • Elisabeth Flo1
Published online: 30 May 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Background and Objective Pain in patients with Alzhei-
mer’s disease is a complex issue; these patients suffer from
the common causes of acute and chronic pain, and some
also have neuropathic or nociceptive pain. Whatever the
mechanism of pain in these patients, their pain will require
careful assessment and management, to insure the correct
type and level of analgesia is given. The objective of this
systematic review was the identification of studies that
have investigated the efficacy of different analgesics on
pain intensity or pain-related behavior during nursing home
stay and at the end of life.
Methods A search using pain, pain treatment, and
dementia MESH terms and keywords was conducted
(October 15, 2015) in MEDLINE, EMBASE, PsychINFO,
CINAHL, and Cochrane libraries.
Results Our search yielded 3138 unique hits, published
between 1990 and October 2015. We read titles and
abstracts, identified 124 papers for full-text evaluation, and
included 12 papers to reflect and synthesize the following
questions: (1) Which pain assessment tools for people with
dementia are responsive to change in pain intensity scores?
(2) Which analgesics are efficacy-tested by controlled trials
including people with dementia living in nursing homes,
including at the end of life? (3) Which outcome measures
have been used to identify pain, pain behavior, and/or
treatment efficacy in people with dementia?
Conclusion Despite increased use of analgesics, pain is
still prevalent in people with dementia. Validated pain
tools are available but not implemented and not fully
tested on responsiveness to treatment. Official guidelines
for pain assessment and treatment addressing people with
dementia living in a nursing home are lacking. The effi-
cacy of analgesic drug use on pain or neuropsychiatric
behavior related to dementia has been hardly
investigated.
Key Points
This systematic review adds to previous reviews of
the assessment and treatment of pain in people with
dementia, with a particular focus on studies
investigating the direct efficacy of analgesics on pain
intensity.
The review underlines current challenges: thorough
pain assessment is poorly implemented,
observational pain instruments are rarely tested for
responsiveness; therefore, sound evaluation of pain
management strategies is lacking and evidence for
efficacy and safety of analgesics is largely missing.
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1 Introduction
It is widely acknowledged that the assessment and treat-
ment of acute and persistent pain is a complex entity in
nursing home patients with Alzheimer’s disease [1]. There
are two extreme endpoints related to these challenges. On
one side, the prevalence of undiagnosed and untreated pain
is described as unacceptably high in the primary health care
system, with reported prevalence up to 32 % in home-
dwelling people with dementia [2] and about 60 % in
nursing home patients with and without dementia [3, 4]. On
the other hand, recent reports document increasing anal-
gesic drug prescription trends, especially in Scandinavia
[5–7], regardless of the potential side effects [8] and the
prevalent polypharmacy in these patients. This picture is
getting even more complex in light of the individual per-
sons who experience the pain. Most of these people
develop changes in their physical function caused by
multimorbidity and increased vulnerability [9]. They have
high needs for motivated and competent nursing home staff
[10], implementation of research-based knowledge [11],
routine use of validated pain assessment tools [12, 13], and
guidelines for appropriate analgesic treatment [14]. This
complex clinical situation is illustrated in the case of Mr. K
(Fig. 1a, b).
Alzheimer’s dementia (AD) and vascular dementia
(VaD) are age-related diseases that have a major impact on
health care resources. At present, 35 million people
worldwide have dementia, with an expected increase to 115
million by 2050 [15]. In advanced stages of dementia, AD
is often combined with VaD to mixed dementia (AD-VaD),
suggested to be the most prevalent in nursing home patients
[4, 16]. These people are more prone to central, neuro-
pathic pain, because lesions in the white matter substance
disturb the connections in the pain system [17].
Despite over a century of scientific endeavor, effective
curative treatment options for these diseases are still
lacking, and increasing frailty and disabilities require
institutional care for more and more individuals. During the
course of the disease, the slight progress of AD substan-
tially affects the motivational and cognitive structures of
the pain network, usually responsible for properly assign-
ing the meaning to pain [1, 12, 13].
In addition to memory disturbances, dementia is com-
monly accompanied by neuropsychiatric symptoms [18]
such as agitation and aggression, depression and apathy,
eating and appetite disturbances, and sleeping disorders
[19]. It is suggested that the causes of these symptoms are
multifactorial, based on chemical, anatomical, and trans-
mitter changes in the brain and/or related to unmet needs.
One important trigger for neuropsychiatric symptoms may
be undiagnosed and untreated pain [20]. However, proper
assessment and treatment of pain in people with dementia
is hampered by the challenge that those in advanced stages
of the disease are no longer able to describe their suffering
and to give precise self-reports regarding the intensity,
location, and duration of the pain [1]. In addition, they are
not able to report appropriate pain relieving effects or side
effects in connection with the pain treatment [13].
General agreement exists that proper assessment of pain
is a prerequisite for proper treatment. During this process,
if self-report is no longer possible, a validated, reliable, and
responsive observational, behavioral pain assessment tool
is required. This means that a proxy rater, usually a nurse
who knows the patient over time, should be able to inter-
pret the patient’s behavior and transfer it into a measure of
pain presence and preferably also into pain intensity [16,
21]. During the last 25 years, about 30 tools have been
developed and tested to assess pain in people with
dementia. Although several review articles present over-
views over such tools [22–29], there is no general agree-
ment on which instrument should be recommended. We
suggest, however, that clinicians and researchers world-
wide appreciate different tools, possibly in relation to the
country in which the respective instrument has been
developed, the availability in that specific country and
language, and the recommendations by national and
regional procedures and guidelines.
Dementia is a life-limiting disease that requires treat-
ment and care in nursing homes or hospitals for almost all
patients at the end of life [30]. This means that the iden-
tification and management of pain in the final weeks and
hours should also be addressed as a key topic [31].
Nonetheless, the effectiveness of a pain treatment
strategy during nursing home stay and at the end of life
cannot be guaranteed by the amount of analgesic drug
prescriptions alone. The way to succeed includes proper
assessment, treatment, and evaluation of the treatment
effect by re-assessment, again using a validated pain tool.
Clearly, this requires nursing home staff who are skilled in
conducting these procedures and a physician who is a
specialist on dementia assessment and communicates well
with the multidisciplinary team.
Although there have been other systematic reviews on
pain in dementia, for instance, on the reliability and
validity of pain scales, this one is the first to look at
important pain management features, such as outcome
measures for pain treatment, responsiveness of pain
observation scales, and efficacy of pain medication. The
main goal of this systematic review is the identification of
studies that directly investigate the efficacy of different
analgesics on pain intensity or typical behavior that might
be related to pain in people with dementia, during nursing
home stay and at the end of life. In order to evaluate the
quality of the included studies, we additionally did an
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updated search based on recent systematic reviews of
behavioral pain assessment tools in people with dementia
published by the authors [1, 13, 21, 32]. The purpose of this
was to be able to ascertain whether the observational pain
tools used in the included efficacy trials were tested for
responsiveness. Thus, we will explore the following
questions:
• Which analgesics are efficacy-tested by clinical or
randomized controlled trials in people with dementia?
• Which outcome measures have been used to identify
pain, pain behavior, and/or pain treatment efficacy?
• Which of the pain assessment tools used for people
with dementia are responsive to change in pain
intensity scores, and thus, adequate to use in a pain
treatment efficacy trial?
2 Method
This systematic review of the literature aims to gather fully
randomized controlled studies with comparator groups or
open studies with more than ten participants that
Mr. K. is 78 years old. For the last 20 months, he has been living in a Norwegian nursing 
home after he developed Alzheimer’s disease, about eight years ago. Mr. K. lost his speech 
ability due to a stroke; this incident also caused a paresis in his right arm. With support by 
staff, he is able to leave his bed and sit in his chair. Recently, the responsible physician 
came to Mr. K.’s nursing home ward. When she entered the unit, she heard a patient 
shouting loudly out of the room. She asked the staff what was going wrong. A nurse 
answered: “Well, Mr. K. is screaming a lot; the screaming started about 14 days ago. We 
discussed his psychiatric problems in our team; we think that he pretends to be in pain. Mr. 
K. is very aggressive and uncooperative during care. Today, he already received a sedative 
drug, but it hasn't worked.” When the nurse together with the physician entered the room of 
Mr. K., he was restlessly sitting in a wheelchair. After transfer into his bed, a systematic 
examination (using the procedure of the MOBID-2 Pain Scale, yielding a score of 8) of 
his body revealed that Mr. K. had a small, red, and infected sacral pressure ulcer. 
In addition, gentle guided movements of his limbs revealed painful stiffness in his right 
shoulder and tenderness in the muscles of the right arm, with upcoming contracture. During 
the consultation, Mr. K. reacted with more restlessness, resistance, and vocalization. It was 
obvious that he was no longer able to describe his pain but responded by changing his usual 
behavior. 
Taking all the observations into account, the physician organized a multidisciplinary meeting
to discuss Mr. K.’s behavior. The primary contact, physiotherapist, and music therapist
were present. They all discussed their perspectives. A systematic work plan was developed 
including the wheelchair function with a comfort pillow, physical therapy with gentle 
massage of the shoulders and greater patience during care. Twice a week, Mr. K. was invited 
to participate in a group of music therapy. 
His drug pain regime was changed from paracetamol 1 g in the evening to paracetamol 1 g 
every eight hours. The neuropathic pain suggested in his right shoulder and arm was treated 
with pregabalin (Lyrica®) 25 mg in the evening, with increased dosage of 25 mg x 2, after 7 
days. However, Mr. K. reacted with confusion and edema in both of his legs; thus pregabalin 
was reduced. Instead, the physician started with buprenorphine transdermal-system 
(Norspan®) 5 µ g/hour/changed every 7th day. Through-out this period Mr. K. was examined 
at least once a week. During the next few days and weeks, the patient was more 
relaxed, less aggressive, and the wound was healing. Again using the MOBID-2 Pain 
Scale, pain intensity scores decreased to 3 and it was possible to withdraw buprenorphine. 
Pregabalin was continued in the lowest dosage administered in the evening. Close 
monitoring and regular control of the pain condition was still required. However, 
the daily situation was inconsistent for Mr. K.; not everything was always optimal, but things 
were much better. The relatives also felt it easier to come to visit. Mr. K. showed more 
pleasure when he met his little grandchild.
a
b
Fig. 1 a The case of Mr. K.
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investigate the efficacy of treating pain on pain intensity
scores and/or behavioral disturbances and neuropsychiatric
symptoms in people with dementia. By this, we will
describe analgesic interventions and assessment procedures
related to the intervention. We recognize that non-phar-
macological interventions in many instances are the first
choice treatment of behavioral disturbances. However, this
is beyond the scope of this current review.
2.1 Literature Search
Assisted by the University Library in Bergen, PICO-based
[problem/population (P), intervention (I), comparison
(C) and outcomes (O) (Table 1)] literature searches were
conducted in October 2015, covering medical peer-re-
viewed publications (original papers and systematic
reviews) published between 1990 and October 2015. We
searched MEDLINE, EMBASE, CINAHL, PsychINFO
and Cochrane libraries (Fig. 2). Key words included
MESH terms and phrases synonymous with ‘‘pain,’’
‘‘treatment,’’ and ‘‘dementia’’ (the online appendix—see
the electronic supplementary material—provides a com-
plete overview of the different MESH terms). The literature
searches were then collated and all the authors discussed
inclusion of publications (see Table 1 for a description of
inclusion and exclusion criteria). To guarantee that we
recognized all the relevant publications, two different
researchers (B. S. H., E. F.) independently selected the
relevant studies. Only articles in the English language were
included. On the basis of the exclusion criteria listed in
Table 1, the authors screened potential manuscripts at the
abstract level and applied the review protocol of described
inclusion and exclusion criteria on selected full texts; we
also searched through the reference lists of the full-text
publications. The authors discussed in group meetings all
manuscripts read in full text and borderline exclusion
cases.
In order to extract and synthesize the content of the
manuscripts included in this review, the authors agreed on
the content to be extracted and developed a data-extraction
table with cells for content to be extracted from the
manuscripts. The table was piloted and discussed in the
group. A minimum of two of the co-authors read through
each publication independently and then verified the data
extraction in a discussion. Any unclear material was raised
in group discussions. When applicable, the following was
extracted from each publication: full manuscript reference,
number of participants, study design and method, type of
intervention (specifically, type of pain medication) and
control condition, time to follow-up, and study setting and
outcomes. Finally, the authors agreed upon the organizing
themes of Tables 2, 3, and 4, and the grading of evidence
according to an adapted Oxford Centre for Evidence-based
Medicine—Levels of Evidence document. This system
allows author to grade both studies and reviews on the
basis of quality factor such as sample homogeneity, follow-
up, definition of comparison group, and use of validated
and relevant tests. The ten different levels of evidence
defined in the system are then translated into grades of
recommendation (A–D).
We had a special focus on articles that described the
responsiveness testing of observational pain assessment
instruments. With responsiveness, we are not referring to
standard error of mean, but to studies demonstrating that
the instrument is responsive to pain treatment. However,
general publications that focused on the development,
validation, and testing of pain assessment tools were
excluded, as these have previously been described in detail
[1, 13, 21, 32].
3 Results
After exclusion of the doublets, the systematic search
generated 3135 unique hits. Subsequently, B.S.H. and E.F.
read the titles and abstracts and identified 124 papers for
full-text evaluation, of which 79 manuscripts were poten-
tial primary studies and 49 were potential systematic
Table 1 Defined PICO-based search strategy, and listed exclusion criteria
Population Patients with Alzheimer’s disease or undefined dementia
Intervention Pain treatment defined as a pharmacological intervention in which the medications employed are named and dosages listed
Comparison All studies using standard care as usual group comparison or other valid comparison alternatives before/after comparison
Outcome Only studies employing quantitative measures and analyses were included. Outcomes included assessment of pain (yes/no or
pain intensity) as well as assessment of pain-related behavior, e.g., neuropsychiatric symptoms
Exclusion
criteria
(1) Qualitative studies, (2) single case studies and those including less than ten patients, (3) methodology papers, (4) study
protocols, (5) animal studies, (6) non-pharmacological studies, (7) deep brain stimulation and other experimental studies, and
(8) conference abstracts. On the basis of these exclusion criteria, the authors screened potential manuscripts at the abstract
level and applied the review protocol of described inclusion and exclusion criteria on selected full texts; we also searched
through the reference lists of the full-text publications
PICO problem/population, intervention, comparison and outcomes
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reviews. A search through the reference lists of the inclu-
ded papers yielded no further publications. Eight studies
yielding 12 publications met the selection criteria (Fig. 2).
These were published between 2003 and 2014, with patient
sample size ranging from 24 to 352, and number of nursing
homes ranging from one to 18. Three studies were pub-
lished by researchers from the USA, two from the
Netherlands, and one study each from Finland, Italy, and
Norway. The quality grading of evidence (grade A–D) is
indicated in Tables 2 and 3. Five of these studies included
typical nursing home patients [33–37], two trials included
dying people [38, 39], and one study had an experimental
design with home-dwelling participants [40]. In four
studies [33, 36, 37, 39], the type of dementia was not
specified among included participants, whereas one study
included only people with AD [40]; in another, almost half
(43 %) of the patients had AD [38]. The remaining two
studies involved people with diagnoses of AD or VaD [34]
and multi-infarct, or degenerative dementia [35]. Six
studies investigated the efficacy of a monotherapy with
paracetamol (acetaminophen), morphine, vitamin D, and
lidocaine gel, while another two studies used several
treatment options and a stepwise protocol of treating pain
(SPTP) (Tables 2, 3).
We did not find intervention studies that included treat-
ment with oral or topical nonsteroidal anti-inflammatory
drugs (NSAIDs), anticonvulsants, tricyclic antidepressants,
tramadol, codeine, or buprenorphine as monotherapy.
Further, we found four papers that described the
responsiveness testing of observational pain assessment
tools (Table 4).
3.1 Which Pain Assessment Tools for People
with Dementia are Responsive to Change in Pain
Intensity Scores?
Responsiveness is the ‘‘ability of an instrument to detect
change over time in the construct to be measured’’ [41].
Thus, a responsive observational pain tool is a prerequisite
for proper treatment of pain in people with dementia to
address the change in the total pain intensity score after
pain treatment has been initiated [21]. Psychometric
property testing of such a tool should follow recent
COnsensus-based Standards for the selection of health
Records idenﬁed through search of the 
MEDLINE, EMBASE, Cinahl, PsychInfo, 



























Full-text arcles assessed for eligibility
(n = 124)
Out of which 49 were potenally 
systemac reviews
Full-text arcles excluded (n = 112)
Mainly due to:
-Not being a systemac review or 
original research paper
- Dealing with ﬁrst line basic animal 
tesng of pharmacological agents
- Not dealing with primary demenng 
illnesses (e.g., demena due to HIV, etc.)
- Not English language
- Not invesgang/deﬁning pain 
treatment procedures
Manuscripts included in Review 
(n = 12)
Studies included from reference lists 
(n = 0)
Fig. 2 PRISMA based flow
chart over the literature search,
selection and review process
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Measurement INstruments (COSMIN) recommendations
[41]. Four validation studies with comparator groups
including between 91 and 352 patients have evaluated the
responsiveness of several observational pain assessment
tools [42–45] (Table 4).
Morello et al. explored the psychometric properties of
the Elderly Pain Caring Assessment 2 (EPCA-2), which
rates the pain intensity in non-communicating elderly
people by eight behavioral items with two dimensions: the
signs outside and during care giving [43]. Patients
(N = 340) from three French hospitals were assessed by
experienced observers (pairs of doctors and nurses) for 7
days, in order to study the patients’ behavior in the absence
of pain and during a presumed state of pain (before and
after taking analgesics). The responsiveness of the EPCA-2
was demonstrated by changes of pain intensity scores that
correlated highly to other change scores of the Global
Clinical Score (GCS) and analgesic drug use (opioid













25 NH patients with
moderate-to-severe
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Patients were more active and spent
more time in social surroundings
and interacting with others
(p\ 0.05, g2 from 0.15 to 0.25); no
effect on agitation, emotional well-














(650 mg 9 4/day) vs. as-needed
acetaminophen administration
DS-DAT No differences were found between
scheduled or as-needed
acetaminophen application;
2600 mg/day acetaminophen is
inadequate for NH patients with
degenerative joint disease







28 people with AD; mean
74 years; baseline MMSE







People with dementia/reduced FAB
show reduced placebo effect of
analgesic treatment [post hoc
Tukey test, q(42) = 13.524,
p\ 0.001]. Analgesics should be
increased to compensate for the





47 people with dementia




All patients received placebo for
4 weeks followed by treatment





25 patients completed the study; no
differences in agitation between
placebo and opioid phases, though
patients C85 years old (N = 13)
were less agitated (CMAI score
-6.4; 95 % confidence interval
-10.96 to -1.8). No group






24 dying patients with most
severe dementia (type
unknown); two NHs;
median age 91 years
Observational study of the last days
of life; small sample size; pain







Mean 4.3 observations per patient; all
participants received morphine
(dosage not available). Low
symptom burden but direct effect






202 NH patients with pain
and dementia (type
unknown); mean
85 ± 7 years; CPS
4.9 ± 1.4, range 1–6
Randomized, double-blind placebo-
controlled 6-month trial with
vitamin D supplement in three






38–84 % of the patients were in pain;
vitamin D deficiency was not
associated to pain or pain behavior;
prevalence of painlessness or pain
scores not changed after vitamin D
treatment
AD Alzheimer’s disease, CMAI Cohen-Mansfield Agitation Inventory [86], CPS Cognitive Performance Scale, DCM Dementia Care Mapping, DS-DAT
Discomfort Scale–Dementia of Alzheimer Type [87], EoL end-of-life, EOLD-CAD End-of-Life in Dementia–Comfort Assessment in Dying [88], FAB
Frontal Assessment Battery [89], GDS Global Deterioration Scale [90], I Italy, MMSE Mini-Mental State Examination [95], NH nursing home, NL
Netherlands, NRS Numerical Rating Scale, PAINAD Pain Assessment in Advanced Dementia [91], RAI Resident Assessment Instrument, rel related to,
VaD vascular dementia
a Quality grade according to the Oxford grading of evidence
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subgroup N = 112, non-opioid subgroup N = 171), com-
pared with the non-analgesic subgroup (N = 57).
Cohen-Mansfield conducted an open pain treatment trial
to investigate the responsiveness of nine observational pain
tools after pain treatment in 121 patients with dementia
living in four nursing homes in Maryland [44]. Patients
(N = 36) with pain at baseline were treated following an
analgesic protocol of paracetamol, oxycodone, or oxycon-
tin. The study had three comparator groups: patients who
were in pain at baseline and treated with the analgesic
protocol; those with pain at baseline, but the primary
caregiver did not follow the protocol; and those without
pain (N = 58). Patients who followed the analgesic treat-
ment protocol had a significant reduction of pain compared
with the other two groups. The Pain Assessment in
Noncommunicative Elderly persons (PAINE) and Pain
Assessment for the Dementing Elderly (PADE) pain tools
were highlighted as the most responsive to assess the
change in pain intensity scores.
The third study, by Rat et al. conducted an open pain
treatment trial to investigate the responsiveness of the acute
pain instrument Algoplus in 91 French hospital patients
with dementia [45]. Acute pain was defined by a list of
pain-inducing situations, such as traumatic injuries, frac-
tures, abdominal pain, or bedsores. Algoplus sensitivity to
change was tested during movement and after starting
acute pain management with World Health Organization
(WHO) level I drug, i.e., non-opioids (37 %), II drug, i.e.,
mild opioids (30 %), III drug, i.e., strong opioids (23 %),
and others (3 %). Paired comparisons by Wilcoxon’s
Table 3 Clinical studies investigating the efficacy of analgesic combination therapy in people with advance dementia
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(2007–2011); 43 %
had AD










In the last week of life, 52 % were
found to be in pain; no differences
between patients between advanced
and less advanced dementia; 77 %
received opioids (90 mg/24 h; 88 %
by injection); 43 % opioid
monotherapy, 57 %
opioids ? paracetamol. Cannot











352 NH patients with
advanced dementia
(type unknown) and
agitation from 60 NH
clusters










Agitation reduced in the SPTP group
(average reduction 17 %
(p\ 0.001, 95 % confidence
interval -3.7 to -10.3) [37].
Verbally agitated behaviors,
physically non-aggressive
behaviors, and aggressive behaviors
improved after 8 weeks (p\ 0.001,
p = 0.008, p = 0.037, respectively)
[50]. Mood syndrome improved
(p\ 0.001), including depression
(p = 0.025), apathy (p = 0.017),
sleep (p = 0.050), and appetite
(p = 0.005) [49]. Pain reduced in
SPTP group compared with control
(p\ 0.001) at week 8, and pain
scores worsened during washout
(p = 0.022). Acetaminophen
improved ADL function (p = 0.02)
[7]
AD Alzheimer’s disease, ADL Activities of Daily Living [52], CMAI Cohen-Mansfield Agitation Inventory [86], CRCT cluster randomized
clinical trial, MMSE Mini-Mental State Examination [95], MOBID Mobilization-Observation-Behavior-Intensity-Dementia [42], N Norway, NH
nursing home, NL Netherlands, NPI-NH Neuropsychiatric Inventory–Nursing Home version [92], NSAID nonsteroidal anti-inflammatory drug,
QoL quality of life, QUALID Quality of Life in Late-Stage Dementia [93], SPTP stepwise protocol of treating pain
a Quality grade according to the Oxford grading of evidence
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signed-rank found Algoplus scores of 3.1 ± 1.3 before
and 1.6 ± 1.1 after treatment, comparable to changes on
the Visual Analog Scale (VAS) and Numerical Rating
Scale (NRS).
Our own group investigated the responsiveness of the
Mobilization-Observation-Behavior-Intensity-Dementia
(MOBID)-2 Pain Scale, using data from a cluster ran-
domized clinical trial that included 352 Norwegian
nursing home patients with advanced dementia and
agitation [42]. Nursing home clusters were randomized
to an SPTP with paracetamol, morphine, or buprenor-
phine, and/or pregabalin when neuropathic pain was
suggested. This was a 12-week trial including a 4-week
washout period after the SPTP. We followed the latest
COSMIN recommendations to assess the responsiveness
of the MOBID-2 Pain Scale. Test–retest reliability
between baseline and week 2 (N = 163), and weeks 2
and 4 (N = 159) was examined in patients not expected
to change (control), using the intraclass correlation
coefficient (ICC2.1), standard error of measurement
(SEM), and smallest detectable change (SDC).
Responsiveness was assessed by testing six a priori-
formulated hypotheses about the relationship between
change scores on the MOBID-2 Pain Scale and other
outcomes. SEM and SDC indicated that the MOBID-2
Pain Scale is responsive to a decrease in pain after
analgesic treatment. Satisfactory test–retest reliability
was demonstrated. Change scores of C3 on total and
subscales were clinically relevant and beyond mea-
surement error.












Randomized study: 284 people were treated
for pain (112 received opioids; 171
received non-opioids; 57 did not receive
any analgesics); investigators not blinded
ES and SRM were correlated with changes in
EPCA-2 scores and GCS, opioid and non-
opioid dosages and demonstrated












Before and after pain treatment evaluation
by self-report and proxy rating; pain
treatment with acetaminophen (N = 29),
combination acetaminophen ? oxycodone
(N = 6) was compared to patients without
pain; investigators not blinded; small
sample size
It is suggested that PAINE and PADE had







Multicenter, cross-sectional study including
five settings. Algoplus sensitivity to
change was tested by movement-induced
change during movement before and after
starting with WHO level I–III analgesics or
non-pharmacological treatment;
investigators blinded
109 acute pain patients received level I drug
(37 %), II drug (30 %), III drug (23 %),
others (3 %). Paired comparisons by
Wilcoxon’s signed-rank found Algoplus
scores before (3.1 ± 1.3) and after
treatment (1.6 ± 1.1) comparable with










Multicenter, cluster randomized trial
including 18 NHs; SPTP with paracetamol,
morphine, buprenorphine and/or
pregabalin; assessments at baseline, week
2 and 4; investigators blinded
SEM and SDC in connection with MOBID-2
Pain Scale measures indicate that the tool is
responsive to a decrease in pain after SPTP.
Satisfactory test–retest reliability
demonstrated. Change scores C3 on total
and subscales are clinically relevant and
beyond measurement error
CNPI Checklist of Nonverbal Pain Indicators [94], EPCA-2 Elderly Pain Caring Assessment 2 [43], ES effect size, GCS global Clinical Score,
MMSE Mini-Mental State Examination [95], MOBID Mobilization-Observation-Behavior-Intensity-Dementia [42], NH nursing home, NRS
Numerical Rating Scale, NVC-OP non-verbally communicating older patients (age C65 years), OPBAI Observational Pain Behavior Assessment
Instrument [96], PADE Pain Assessment for the Dementing Elderly [97], PAINAD Pain Assessment in Advanced Dementia [91], PAINE Pain
Assessment in Noncommunicative Elderly persons [98], SDC smallest detectable change, SEM standard error of measurement, SPTP stepwise
protocol of treating pain, SRM standard response mean, VAS Visual Analog Scale, WHO World Health Organization
a Informant rating
b Observation rating
c Acute pain tool
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3.2 Which Analgesics are Efficacy-Tested
by Clinical or Randomized Controlled Trials
Including People with Dementia?
3.2.1 Paracetamol
The use of paracetamol is recommended as the first-line
therapy in people with dementia [14] and is to date the
most used analgesic in nursing home patients worldwide
[46, 47]. We found two studies conducted between 1998
and 2015 that investigated the efficacy of paracetamol
(administered as monotherapy) on pain and/or behavioral
disturbances in people with dementia (Table 2).
Chibnall et al. conducted a placebo-controlled, cross-
over trial for 4 weeks including 25 people with moderate to
severe dementia [35]. Twenty-five patients received
4 weeks’ paracetamol 1 g each 8 h and 4 weeks’ placebo
in random order, with a 1-week washout period; 23 patients
completed both study phases. The effect was assessed with
Dementia Care Mapping (DCM) and Cohen-Mansfield
Agitation Inventory (CMAI) [35]. Results demonstrated
that patients in the intervention phase were more active and
interacted with each other, and spent more time in social
surroundings. Paracetamol, however, did not ameliorate
agitation, improve emotional well-being, or reduce the use
of as-needed psychotropic medication. A validated pain
assessment tool was not used.
Buffum et al. included 39 nursing home patients with
advanced dementia and degenerative joint diseases in a
placebo-controlled, crossover trial for 4 weeks (each arm
lasted for 2 weeks) to investigate the impact of regularly
scheduled analgesic treatment compared with as-needed
administration [34]. Patients randomized to the interven-
tion group received 2.6 g paracetamol in 24 h. The treat-
ment effect was assessed by the Discomfort Scale–
Dementia of Alzheimer Type (DS-DAT). No differences in
pain and/or discomfort were found between the groups. It
was suggested, however, that the paracetamol dosage was
rather too low to ameliorate existing pain.
3.2.2 Opioids
We found two studies that investigated the efficacy of
morphine and oxycodone (as a monotherapy) on neu-
ropsychiatric symptoms, pain, and overall symptom man-
agement in people with dementia (Table 2). Manfredi et al.
conducted a small double-blinded, crossover study with
fixed treatment order for 8 weeks and included 47 people
with moderate to severe dementia and behavioral distur-
bances from one nursing home [36]. Participants started
with 4-week placebo treatment, and after a 1-day interval, a
long-acting opioid (long-acting oxycodone 10 mg every
12 h, or for patients who could not swallow pills, long-
acting morphine 20 mg once a day, via a feeding tube) for
the next 4 weeks. This approach did not include a ran-
domized order of administration. The efficacy of opioid
treatment on agitation was assessed by the CMAI, and no
significant differences were found between the placebo and
active phases in 25 participants who completed the study.
Sub-analyses demonstrated, however, that 13 patients older
than 84 years were less agitated. An observational pain
assessment instrument was not used.
The second study, by Klapwijk et al. was an open
prospective, observational follow-up trial in two Dutch
nursing homes, and included 24 people with severe
dementia who were expected to die within the next 7 days
[39]. The judgment that the patient was perceived as dying
was based on an estimation made by the treating physician
and responsible nurse. Symptoms of discomfort, pain, and
suffering were recorded twice a day using the Pain
Assessment in Advanced Dementia (PAINAD), DS-DAT,
and End-Of-Life in Dementia–Comfort assessment in
Dying (EOLD-CAD) scales, and an adapted version of the
Mini-Suffering State Examination (MSSE). Pain and dis-
tressing symptoms were treated with morphine. Each
patient was observed several times (mean 4.3) until they
died, demonstrating low intensity scores of pain and other
symptoms such as dyspnea and fear. However, the direct
effect of morphine on pain or other distressing symptoms,
and the exact dosages, were not available.
3.2.3 Lidocaine (1 % Solution)
Benedetti et al. included 28 non-consecutive, commu-
nicative, home-dwelling patients with AD and 16 healthy
volunteers matched for sex and age (mean 74 years) [40].
Participants were invited to take blood samples in the
laboratory. This procedure is often described as a burning
sensation and, thereby, patients are treated with the local
anesthetic lidocaine (1 % solution). In the open (expected)
condition, the drug was applied in full view of the patient,
whereas in the hidden (unexpected) condition, the same
dose of drug was administered with the patient completely
unaware that a local anesthetic was being applied. To
justify the lack of lidocaine application, the patients were
told that lidocaine would be applied or not. Patients rated
their pain sensation on an NRS. Results demonstrated that
AD patients showed reduced placebo component of the
analgesic treatment. Loss of the placebo-related mecha-
nism reduced treatment efficacy, such that a dose increase
was necessary to produce adequate analgesia.
3.2.4 Vitamin D
Bjo¨rkman et al. investigated the efficacy of vitamin D (c-
holecalciferol) treatment on pain during a 6-month, double-
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blind, placebo-controlled clinical trial [33]. The study
participants were assessed by the Resident Assessment
Instrument (RAI) and DS-DAT (Table 2). Two hundred
and two nursing home patients with cognitive impairment
were randomized to three groups, which were treated with
0, 400, or 1200 IU cholecalciferol. Despite growing evi-
dence of the potential benefit of vitamin D supplementation
on pain intensity, the etiology was still vague after
6 months of treatment.
3.2.5 Multi-Analgesic Drug Use
We identified two studies that investigated multi-analgesic
stepwise drug use to treat pain and/or neuropsychiatric
symptoms in people with dementia (Table 3). Results were
published in six different articles [7, 37, 38, 48–50]. The
first study, by Hendriks et al. included 330 dying people
with dementia from 34 Dutch nursing homes (2007–2011)
[38]. The End of Life in Dementia (EOLD) study is an
open, longitudinal, observational trial with a 3.5-year fol-
low-up, until death. The responsible physicians performed
assessments at baseline, semiannually, and 2 weeks after
death. The occurrence of pain, dyspnea, and agitation were
scored dichotomously (present/not present). The quality of
life was assessed by the Quality of Life in Late-stage
Dementia (QUALID) scale. Independent of the stage of
dementia, 52 % of the patients were registered as in pain in
the last week of life. Most of the patients (77 %) received
opioids (90 mg/24 h; 88 % by injection); opioid
monotherapy was applied to 43, and 57 % of the dying
received morphine combined with paracetamol. The sec-
ond publication by Hendriks and colleagues investigated
the associations between the symptoms of pain and agita-
tion, as well as between the stage of dementia and symp-
toms [48]. They found that the prevalence of pain ranged
from 47 % to 68 % across the semiannual assessments, and
increased to 78 % in the last week of life. Symptom
treatment changed in particular at the end of life. Pain was
treated mostly with paracetamol (34–52 %), and at the end
of life with parenteral opioids (44 %). Pain and agitation
were common and frequently persisted in residents with
dementia during nursing home stay, but symptom man-
agement intensified only at the end of life. The authors
concluded that symptom control may be suboptimal start-
ing at admission, and this requires a stronger focus on
symptom control at earlier stages than only the last days or
weeks of life.
Our own study, described earlier, was a cluster ran-
domized clinical trial over 12 weeks, including 352 people
with advanced dementia and neuropsychiatric symptoms
from 18 nursing homes in Norway [37]. Patients random-
ized to intervention received an SPTP with paracetamol,
morphine, buprenorphine, and/or pregabalin on the basis of
ongoing treatment and individual needs. The MOBID-2
Pain Scale, CMAI, Neuropsychiatric Inventory–Nursing
Home version (NPI-NH), and the Activities of Daily Liv-
ing (ADL) scales were regularly used for data collection at
baseline, weeks 2, 4, 8, and 12 (weeks 8–12 washout).
Analyses found agitation reduced in the SPTP group after 4
weeks (average reduction 17 %; p\ 0.001). Verbally
agitated behaviors, physically non-aggressive behaviors,
and aggressive behaviors improved significantly
(p\ 0.001, p = 0.008, p = 0.037, respectively) after 8
weeks [50]. Mood syndrome improved (p\ 0.001),
including depression (p = 0.025), apathy (p = 0.017),
sleep (p = 0.050), and appetite (p = 0.005), but not irri-
tability (p = 0.092) and anxiety (p = 0.125) [49]. Pain was
reduced in the SPTP group compared with control
(p\ 0.001) at week 8, and MOBID-2 scores and agitation
worsened during the washout period (p = 0.022). Exam-
ining different analgesic treatments, patients receiving
paracetamol improved significantly in their ADL function
(p = 0.022) [7].
3.3 Which Primary and Secondary Outcome
Measures Were Used?
Five studies used a pain assessment instrument (NRS–self-
rating, DS-DAT, MOBID-2 Pain Scale, RAI, and PAI-
NAD) to investigate the efficacy of treating pain on pain
intensity. Of these instruments, the MOBID-2 Pain Scale is
the only instrument that has been tested for responsiveness
in dementia patients [42] (Tables 2, 3). Some papers
investigated the efficacy of treating pain on indirect mea-
sures, such as agitation, neuropsychiatric symptoms, qual-
ity of life, activity, and more general symptom control at
the end of life (CMAI, NPI-NH, ADL, QUALID, DCM,
EOLD-CAD). For the QUALID, a measure for quality of
life in dementia, there has been only one study on
responsiveness, which showed that it was not responsive to
changed neuropsychiatric symptoms [51]. Quality of life
was related to neuropsychiatric symptoms at baseline and
after intervention, but not related to change scores. The
instruments that measure neuropsychiatric symptoms
(CMAI and NPI-NH) have been proven responsive to
several (non-)pharmacological behavioral interventions.
CMAI was also responsive to pain medication in one study
[37]. In the same study sample, the NPI-NH subscale mood
was also responsive to pain medication [7], as was the ADL
measure [52]. We could not find other studies in which
responsiveness was tested on the effect of pain medication
in a dementia population.
The EOLD-CAD is an instrument that measures quality
of dying and performs well in terms of validity, reliability,
and feasibility [53]. However, there are no data on its
responsiveness, or studies showing relevant differences
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after pain interventions. The DCM tool (a direct observa-
tion tool, developed for use in nursing homes) has been
shown to be able to pick up changes in activity after an
intervention with paracetamol, although no formal
responsiveness test results are presented [35].
4 Discussion
This article adds to previous literature reviews of the
assessment and treatment of pain in people with dementia
[1, 12, 21, 54, 55], with a particular focus on studies
investigating the direct efficacy of analgesics on pain
intensity. In this context, it was also important to give an
overview of responsive tools that are able to assess change
in the total pain intensity score after initiation of the
treatment. We further extended our search to studies that
included dying people with dementia because it is widely
acknowledged that dementia is a life-limiting disease with
considerable pain and symptom burden in the last days and
hours of life [31, 56, 57].
4.1 Methodological Perspectives
We found few studies employed a blinded, controlled trial
design; they generally included few participants; and
unfortunately, most of the publications did not sufficiently
describe management of dropouts. The possible lack of
statistical power and selection bias means that the studies
in this review may have methodological and statistical
biases. There was also a wide variation both in the inter-
ventions used and in the study designs.
Hence, a limitation with our systematic literature review
is the limited possibility to compare the studies in terms of
quality and methods. Conclusive recommendations based
on aggregated evidence are at this point difficult to provide.
In addition, with our strict inclusion criteria, we cannot
exclude the possibility of publication bias.
4.2 Responsiveness of Pain Assessment Tools
Thus far, few studies have investigated the responsiveness
of pain assessment tools used in people with dementia or
non-communicating elderly people. Responsiveness is of
critical importance for clinicians and researchers to be
confident that an improvement in individual patients after
treatment is not merely measurement error. The results of
the few responsiveness studies of the single measurement
tools are challenging to interpret because treatment groups
were partly small with different treatment and measure-
ment approaches.
The initial step to improve pain treatment is proper
assessment by monitoring the change of pain intensity to
the pain treatment intervention. We found four studies that
reported the responsiveness of the observational tools
EPCA-2 [43], MOBID-2 Pain Scale [42], PAINE and
PADE [44], developed and tested for nursing home patients
with dementia, and the Algoplus for the evaluation of
acute pain treatment in hospital [45]. However, the evi-
dence to support the use of these pain tools is rather lim-
ited. Recent requirements by the COSMIN group
recommended a checklist for assessing the methodological
quality of health status measurement instruments to
improve the psychometric property testing [41]. Until now,
only the MOBID-2 Pain Scale followed the latest COSMIN
recommendations and examined measurement error by the
SEM and the SDC, which are important parameters for
judging change scores in large clinical trials investigating
the efficacy of analgesics on pain intensity [7]. To the best
of our knowledge, there are currently no other instruments
that have been responsiveness tested for use in dying
people with dementia [53]. Consequently, the direct effi-
cacy of pain and symptom management cannot currently be
monitored by a responsive tool at the end of life in these
individuals. Studies on responsive non-verbal pain assess-
ment tools in the end-of-life setting are needed.
4.3 Pain Assessment in Dementia
Today, there is extensive ongoing work to develop and test
appropriate pain assessment instruments for people with
advanced dementia [58]. Most of the instruments are based
on the assumption and recommendations of the American
Geriatrics Society (AGS) Panel that pain can be expressed
by changes in facial expression (e.g., frowning), vocaliza-
tion and verbalization (e.g., groaning, mumbling), and
body movements [59, 60]. The AGS Panel suggests the
following additional behavioral changes that may be trig-
gered by untreated pain: changes in interpersonal interac-
tions (e.g., aggressive, combative, resisting care), changes
in activity patterns or routines (e.g., wandering, appetite,
sleep), and mental status changes (e.g., crying, confusion,
irritability). One important clinical and research dilemma is
the difficulty of differentiation between typical behavior
related to pain and behavior that is caused by the dementia
process itself. These behaviors may present in a similar
way for the observer [21]. Importantly, most scales are
validated for ascertaining the presence of pain, but not the
pain intensity. In most scales, we do not know if scoring a
higher number of behavioral items also means more pain.
In addition, in these scales, all behavioral items that can be
scored are given the same weight. No studies have tried to
differentiate pain intensity between these items, and
therefore, we cannot say if, for instance, guarding, frown-
ing, or screaming is an indication of more pain. Conse-
quently, we need more research on the responsiveness of
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these behavioral pain observation scales, and these should
not only be studied on the change of sum scores. Sensitive
responsive instruments are needed for the evaluation of
pain treatment, and they will also require weighing of the
different behavioral signs.
The psychometric property developments (validity,
reliability, and responsiveness) of available instruments are
ongoing tasks. General agreement exists that the assess-
ment of pain in people with dementia should be based on
the observation of the patient’s pain behavior during
activities of daily living and/or gentle guided standardized
movements, because pain avoidance may mask pain
behavior [21, 58, 60–62]. The interpretation of pain
behavior into pain intensity scores is a necessary task
because the presence of the behavior does not automati-
cally mean clinically significant pain intensity. As
demonstrated by the MOBID-2 Pain Scale, the differenti-
ation between pain related to the muscle-skeletal system
and internal organs, head, and skin is relevant for the
clinician, since different locations of pain may require
different treatment approaches. The nursing staff need to
have their daily observations systematized and corrobo-
rated by a validated total pain intensity score. A cut-point
will indicate when to contact the physician who continues
further evaluations and treatment.
4.4 Pharmacological Management of Pain
in Dementia
We identified eight randomized prospective treatment trials
with a comparator group or open studies with more than ten
participants that investigated the direct effect of analgesics
on pain and/or neuropsychiatric symptoms including peo-
ple with dementia. Importantly, only four of these studies
used a pain assessment instrument to monitor the analgesic
treatment effect on pain intensity. There is limited evidence
as to the effect of using paracetamol and morphine. We are
not aware of studies that included treatment with NSAIDs,
tramadol, or codeine. However, Stein et al. conducted a
3-month, randomized, controlled trial to investigate the
efficacy of an educational program for nursing home staff
to improve pain treatment and indirectly reduce the use of
NSAIDs [63]. The education of staff resulted in a reduction
of the time of NSAID use from 7 to 2 days and from 7 to
6 days in the control group. Interestingly, the reduction did
not worsen the pain [63]. Buprenorphine and pregabalin
have only been used in one large, cluster randomized,
controlled trial that offered a stepwise approach to treating
pain [37].
Although paracetamol is traditionally the most used
analgesic drug in nursing homes [46], we found only two
trials that investigated the efficacy of this treatment on pain
intensity and/or behavioral disturbances in people with
dementia. Both studies were randomized, placebo-con-
trolled, crossover trials and demonstrated inconsistent
results. Chibnall included 25 patients who received 4
weeks of paracetamol (3 g/day) and 4 weeks of placebo
[35]. Patients randomized to the intervention group were
more active and spent more time in social surroundings.
The efficacy on pain intensity scores was not investigated
by a validated pain tool. Buffum et al. investigated the
efficacy of regularly scheduled paracetamol for discomfort
in people with advanced dementia over 4 weeks (2-week
treatment with scheduled vs. 2-week treatment with as-
needed administration) [34]. Assessed by the DS-DAT,
regular use of paracetamol did not confer any benefit
compared with as-needed administration of the drug.
Interestingly, the authors found that a dosage of 2600 mg
paracetamol per day was not adequate to ameliorate pain in
connection with degenerative joint disease. Agitation, as
well, was not reduced by the treatment [34]. The only trial
that directly investigated the effect of morphine
monotherapy on pain intensity was a placebo-controlled,
crossover trial including 47 nursing home patients with
dementia [36]. Manfredi et al. found reduction of agitation
in patients aged 85 or older, suggesting that opioids used in
very old patients may be a beneficial treatment for agitation
[36]. The impact on pain intensity scores was not assessed.
All the three studies were small and underpowered cross-
over trials; the results are challenging to interpret because
of this and because of the lack of pain assessment instru-
ments or low doses of paracetamol.
Two other placebo-controlled trials need attention
because of their robust methodologies, sample sizes, and
innovative research questions. Benedetti et al. included 28
people with mild to moderate AD; they were younger
(mean 74 years) and lived at home [40]. Using lidocaine
gel during a painful procedure, the investigators demon-
strated a reduction of the placebo component in patients
with dementia. It was concluded that pain treatment should
be adjusted to compensate for the loss of placebo effect
[40]. The other study, by Bjo¨rkman et al. included 202
people with dementia and explored the efficacy of treating
pain with vitamin D supplementation in three groups [33].
Pain was assessed by three different pain tools (RAI,
PAINAD, and DS-DAT). However, the authors did not find
any effect of vitamin D on pain or pain behavior; neither
prevalence of painlessness nor pain scores changed after
vitamin D treatment [33]. One large cluster randomized
study supported guidelines from the AGS panel by a
stepwise protocol of treating pain in people with dementia
demonstrating clinically relevant agitation and pain [37].
The study demonstrated that low doses of morphine and
buprenorphine were well tolerated and ameliorated pain in
people with dementia. Also paracetamol was a safer
alternative medication than psychotropic drugs and
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improved activities of daily living [7]. In people with
neuropathic pain, pregabalin significantly reduced the pain
intensity scores [7]. Finally, the mood syndrome was
improved by individual pain treatment [49]. However, this
study was not placebo controlled and the results should be
validated by a well powered trial using active and placebo
analgesics.
4.5 Pain Treatment in Dying Patients
with Dementia
The needs of people with dementia at the end of life may
be different from those with different diseases [64, 65].
Thus, it was important for us to also include two obser-
vational studies of palliative treatment that described the
effectiveness of analgesics on pain intensity scores or
symptom burden in these individuals. The prospective
observational study by Klapwijk et al. observed 24 patients
from the day when the person was perceived as dying and
to the day of death [39]. All patients received morphine
subcutaneously. Although the most used pain assessment
instruments (PAINAD, DS-DAT) were not validated for
this end-of-life situation, the multidisciplinary team was
pleased with the pain and symptom relieving effect of the
treatment [39]. The study by Hendriks et al. included 330
dying patients, who were retrospectively (up to 2 weeks
after death) assessed by 103 elderly care physicians [38,
48]. Fifty-two percent of the patients were affected by pain,
which was dichotomized as present or not, and were treated
with 90 mg morphine/24 h on the day of death. Both
studies are groundbreaking contributions to the assessment
and treatment of pain and burdensome symptoms in dying
people with dementia, although the study by Klapwijk et al.
was somewhat underpowered and the study by Hendriks
et al. retrospective. Both studies were observational; thus,
the direct effect of the analgesics was difficult to interpret.
Pain research in dying people with dementia is of par-
ticular interest for several reasons. First, research including
elderly patients often excludes people with dementia and,
until now, especially dying people with dementia [66–68].
Further, palliative care for cancer patients cannot neces-
sarily be transferred to dying people with dementia [69].
These individuals are neither able to describe the pain nor
the pain treatment effect or side effects. Third, the nature of
dementia leads to reduction of the neurotransmitter
acetylcholine, responsible for neuromuscular junction and
muscle activities, and the autonomic, sympathetic, and
parasympathetic nervous system. Consequently, drugs that
affect the cholinergic systems (anticholinergic drugs) can
have very dangerous effects, ranging from paralysis to
convulsions [70]. Importantly, most of the drugs used in
palliative care (morphine, scopolamine, or midazolam) to
relieve pain and distressing symptoms have anticholinergic
side effects. A self-fulfilling prophecy may be the case
when a patient with dementia is wrongly identified as dying
and then receives this treatment, hastening the death. These
challenges argue for the urgent need for clinical studies,
disease-specific guidelines, and implementation of
research-based knowledge [31].
4.6 Analgesic Drug Prescription
Fifteen years ago, researchers echoed that people with
advanced dementia have a substantial risk for undetected or
undertreated pain. Morrison and Siu examined the treat-
ment of pain following hip fractures in a prospective cohort
study and found that people with advanced dementia
received only one-third the amount of morphine compared
with cognitively intact patients [71]. Another study, by
Closs et al. explored analgesic prescription according to
cognitive status in nursing home patients and found no
differences in pain scores, but administration of opioid and
non-opioid analgesics were highest for residents without
dementia [72]. Results are supported by a more recent
study from the USA, which identified nursing home
patients with similar pain-related diagnoses; patients
without dementia received significantly more opioids
compared with those with cognitive impairment, despite
higher pain intensity scores based on interviews and use of
a numeric rating scale [73]. In addition, there are many
other studies that confirm the under-treatment of pain in
people with dementia in the community, residential care
settings, nursing homes, and hospitals [3].
Nevertheless, times are changing. Recent prevalence
studies demonstrated new trends of analgesic drug use. In
the Kungsholmen Study, 46 % of 2610 people with
dementia used at least one analgesic drug compared with
25 % of those without dementia [5]. Another nationwide
Swedish study demonstrated that centenarians
([100 years) used more analgesics, anxiolytics, and hyp-
notics compared with younger patients [74]. Indeed, the
use of analgesics in 546 older people ([85 years), with and
without dementia, at home and in the nursing home, was
high in Sweden and Finland. People with dementia used
more paracetamol and likewise amounts of opioids com-
pared with those without cognitive impairment [75]. In
addition, the use of strong opioids (e.g., transdermal fen-
tanyl) was higher in people with dementia in Finland [76].
In Danish nursing home patients, 41 % of all elderly
receive opioids, and those with dementia and nursing home
residents have a higher chance of receiving opioids [77].
Most importantly, none of these studies reported better
accuracy of pain assessment procedures, higher or
improved pain management effects, or side effects of the
treatment. This is of key importance because, based on
Rhode Island Medicaid pharmacy claims about nursing
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home data, the US Food and Drug Administration (FDA)
warned against morbidity and death related to the launch of
long-acting opioids and the fentanyl transdermal system in
opioid-naive people with AD [78]. The authors found these
drugs more frequently prescribed in those with advanced
age and increased cognitive impairment. Recently, our own
research demonstrated almost a doubling of analgesics,
from 35 to 58 %, in Norwegian nursing homes during the
last 10 years (2000–2011) [47]. Results support recent
trend analyses, which found that the use of analgesic drugs
has been increasing rapidly over the last 8 years [79]. It
seems a paradox, however, that the crucial question
remains: does the right patient receive the right medication
for the proper indication at the right time [1]? Although
few of the recent studies suggest that analgesics are sys-
tematically under-prescribed, there is no information
whatsoever on assessment, indication, evaluation, benefits,
and harms [80]. Thus, attaining a competent balance
between under- and overuse of analgesics in people with
dementia remains the most important challenge in this
field.
Getting older is associated with a progressive decline of
organ function, including typical changes such as reduced
body mass index and lower body water percentage com-
pared with a higher fat mass percentage [70]. This is often
combined with latent insufficiency of liver, a lower
glomerular filtration rate of the kidneys, and cognitive
function and biological alterations (such as a lower total
brain mass) that impact the pharmacodynamics and phar-
macokinetics of the drug. The absorption, distribution, and
elimination of the drugs are altered, especially when sev-
eral drugs are combined as a result of polypharmacy. Beers
Criteria highlight a greater sensitivity to adverse events and
higher risks of side effects in these people [81]. However,
we did not find studies that investigated pharmacodynam-
ics and pharmacokinetics of analgesic drugs in people with
dementia. Being aware of the potential lack of placebo
effect in dementia and the potential effects of dementia on
the brain–blood barrier certainly warrants those studies.
4.7 Pain Treatment Recommendations
Although best practice recommendations for the assess-
ment and treatment of pain in elderly people are available
[12, 14, 23, 59, 60, 82–84], clinicians in the nursing home
setting may not routinely follow—or even be aware of—
these guidelines. These expert groups predominantly
endorse some specific drugs: paracetamol, strong opioids,
and anticonvulsants [12, 14, 23, 59, 60, 82–84]. Results of
this review, however, underline the weak evidence base for
all analgesics in dementia. Although the process of
developing new evidence, the foundation of clinical
guidelines and implementation, is not always linear, there
is still a lack of well powered randomized controlled trials,
and this prevents definite clinical guidelines being imple-
mented among clinical staff [85]. There is some evidence
that paracetamol can be recommended, as it is relatively
safe and some studies underline its efficacy. We therefore
stress the need for placebo-controlled, randomized studies
not only investigating the efficacy of NSAIDs, anticon-
vulsants, and morphine, but also withdrawal studies
including patients who no longer are in need of these drugs.
5 Conclusion
To conclude, this review underlines the serious situation
that pain management in especially advanced dementia is
in at this moment: thorough pain assessment is poorly
implemented and observational pain instruments have been
scarcely tested for responsiveness; therefore, effective
evaluation of pain management strategies is lacking and
evidence for efficacy and safety of analgesics is largely
missing. We emphasize the critical need for future research
with well powered pain medication trials in persons with
moderate to severe dementia using pain assessment tools
that have been tested for responsiveness. Furthermore,
there is a high need for studies investigating the end-of-life
care in this population.
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